 Ronina Covar
Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 77 | 2023 | 1797 | 5.880 |
Why?
| | Anti-Asthmatic Agents | 29 | 2021 | 260 | 3.170 |
Why?
| | Bronchial Provocation Tests | 6 | 2022 | 47 | 1.520 |
Why?
| | Bronchodilator Agents | 15 | 2019 | 187 | 1.480 |
Why?
| | Adrenal Cortex Hormones | 15 | 2022 | 484 | 1.410 |
Why?
| | Respiratory Sounds | 12 | 2022 | 103 | 1.210 |
Why?
| | Budesonide | 9 | 2016 | 49 | 1.080 |
Why?
| | Bronchial Hyperreactivity | 5 | 2018 | 104 | 1.010 |
Why?
| | Eosinophilia | 2 | 2023 | 223 | 0.800 |
Why?
| | Nedocromil | 5 | 2016 | 20 | 0.770 |
Why?
| | Albuterol | 10 | 2018 | 76 | 0.770 |
Why?
| | Administration, Inhalation | 22 | 2022 | 571 | 0.760 |
Why?
| | Glucocorticoids | 11 | 2019 | 531 | 0.750 |
Why?
| | Androstadienes | 7 | 2016 | 75 | 0.750 |
Why?
| | Fluticasone | 10 | 2019 | 53 | 0.730 |
Why?
| | Respiratory Function Tests | 13 | 2018 | 544 | 0.720 |
Why?
| | Lung | 8 | 2022 | 4106 | 0.700 |
Why?
| | Forced Expiratory Volume | 16 | 2022 | 450 | 0.630 |
Why?
| | Respiratory Mechanics | 1 | 2020 | 74 | 0.600 |
Why?
| | Anti-Inflammatory Agents | 10 | 2016 | 477 | 0.590 |
Why?
| | Leukotriene Antagonists | 6 | 2016 | 24 | 0.580 |
Why?
| | Mediastinal Emphysema | 1 | 2018 | 9 | 0.540 |
Why?
| | Nitric Oxide | 6 | 2023 | 892 | 0.530 |
Why?
| | Child | 49 | 2023 | 22707 | 0.460 |
Why?
| | Acetates | 7 | 2014 | 78 | 0.460 |
Why?
| | Double-Blind Method | 19 | 2021 | 2062 | 0.430 |
Why?
| | Quinolines | 7 | 2014 | 190 | 0.420 |
Why?
| | Marijuana Smoking | 1 | 2018 | 249 | 0.420 |
Why?
| | Eosinophils | 6 | 2023 | 316 | 0.410 |
Why?
| | Sputum | 4 | 2023 | 302 | 0.380 |
Why?
| | Precision Medicine | 4 | 2021 | 459 | 0.380 |
Why?
| | Adrenergic beta-Agonists | 4 | 2013 | 92 | 0.370 |
Why?
| | Child, Preschool | 35 | 2022 | 11853 | 0.370 |
Why?
| | Humans | 85 | 2023 | 145474 | 0.360 |
Why?
| | Cannabis | 1 | 2018 | 509 | 0.320 |
Why?
| | Phenotype | 4 | 2020 | 3155 | 0.320 |
Why?
| | Eicosapentaenoic Acid | 1 | 2010 | 37 | 0.310 |
Why?
| | Biomarkers | 10 | 2023 | 4295 | 0.310 |
Why?
| | Salmeterol Xinafoate | 6 | 2019 | 20 | 0.300 |
Why?
| | Docosahexaenoic Acids | 1 | 2010 | 88 | 0.300 |
Why?
| | Adolescent | 31 | 2022 | 22529 | 0.290 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2021 | 1747 | 0.280 |
Why?
| | Ibuprofen | 2 | 2021 | 87 | 0.280 |
Why?
| | Male | 53 | 2020 | 72842 | 0.260 |
Why?
| | Spirometry | 9 | 2022 | 233 | 0.260 |
Why?
| | Drug Therapy, Combination | 7 | 2016 | 1044 | 0.250 |
Why?
| | Breath Tests | 3 | 2023 | 77 | 0.240 |
Why?
| | Antioxidants | 1 | 2010 | 550 | 0.240 |
Why?
| | Female | 52 | 2020 | 78844 | 0.240 |
Why?
| | Disease Progression | 9 | 2018 | 2864 | 0.230 |
Why?
| | Treatment Outcome | 15 | 2019 | 11772 | 0.220 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2022 | 919 | 0.220 |
Why?
| | Pulmonary Ventilation | 1 | 2005 | 82 | 0.210 |
Why?
| | Microbiota | 2 | 2023 | 730 | 0.200 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 229 | 0.200 |
Why?
| | Beclomethasone | 2 | 2015 | 8 | 0.200 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2005 | 252 | 0.200 |
Why?
| | Severity of Illness Index | 12 | 2021 | 2930 | 0.190 |
Why?
| | Mycobiome | 1 | 2023 | 8 | 0.190 |
Why?
| | Ribonucleases | 1 | 2003 | 48 | 0.190 |
Why?
| | Larynx | 1 | 2023 | 56 | 0.190 |
Why?
| | Respiration | 1 | 2003 | 206 | 0.180 |
Why?
| | Antigens, Dermatophagoides | 1 | 2022 | 10 | 0.180 |
Why?
| | Muscarinic Antagonists | 1 | 2022 | 30 | 0.180 |
Why?
| | Airway Obstruction | 2 | 2022 | 153 | 0.180 |
Why?
| | Dietary Supplements | 2 | 2020 | 583 | 0.180 |
Why?
| | Azithromycin | 2 | 2015 | 101 | 0.180 |
Why?
| | Prospective Studies | 8 | 2023 | 8057 | 0.180 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 345 | 0.170 |
Why?
| | Prednisone | 4 | 2016 | 224 | 0.170 |
Why?
| | Models, Biological | 1 | 2008 | 1764 | 0.170 |
Why?
| | Vitamin D Deficiency | 2 | 2020 | 190 | 0.160 |
Why?
| | Cholecalciferol | 1 | 2020 | 61 | 0.160 |
Why?
| | Leukocyte Count | 4 | 2019 | 316 | 0.150 |
Why?
| | Methacholine Chloride | 3 | 2022 | 51 | 0.150 |
Why?
| | Infant | 15 | 2022 | 10077 | 0.150 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 26 | 0.150 |
Why?
| | Cross-Over Studies | 6 | 2019 | 608 | 0.150 |
Why?
| | Mometasone Furoate | 1 | 2019 | 3 | 0.150 |
Why?
| | Tiotropium Bromide | 1 | 2019 | 5 | 0.150 |
Why?
| | Symbiosis | 1 | 2019 | 72 | 0.140 |
Why?
| | Vitamins | 1 | 2020 | 182 | 0.140 |
Why?
| | Social Class | 1 | 2021 | 264 | 0.140 |
Why?
| | Minority Groups | 1 | 2021 | 284 | 0.140 |
Why?
| | Population | 1 | 2018 | 30 | 0.140 |
Why?
| | Risk Factors | 8 | 2016 | 10885 | 0.140 |
Why?
| | Cyclopropanes | 7 | 2014 | 84 | 0.130 |
Why?
| | Acetaminophen | 2 | 2021 | 267 | 0.130 |
Why?
| | Education | 1 | 2018 | 104 | 0.130 |
Why?
| | Sulfides | 7 | 2014 | 92 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2021 | 1581 | 0.130 |
Why?
| | Patient Selection | 1 | 2021 | 738 | 0.120 |
Why?
| | Benzyl Alcohols | 1 | 2016 | 2 | 0.120 |
Why?
| | Chlorobenzenes | 1 | 2016 | 18 | 0.120 |
Why?
| | Airway Remodeling | 1 | 2016 | 63 | 0.120 |
Why?
| | Eczema | 2 | 2014 | 66 | 0.120 |
Why?
| | Child Care | 1 | 2016 | 36 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 3 | 2021 | 2769 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2019 | 2028 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 3 | 2016 | 2378 | 0.110 |
Why?
| | Adult | 13 | 2023 | 40777 | 0.110 |
Why?
| | Bronchoconstrictor Agents | 2 | 2006 | 14 | 0.110 |
Why?
| | Anti-Bacterial Agents | 3 | 2015 | 1923 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2016 | 500 | 0.110 |
Why?
| | Lectins | 1 | 2014 | 44 | 0.100 |
Why?
| | Drug Administration Schedule | 5 | 2016 | 782 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2015 | 251 | 0.100 |
Why?
| | Adipokines | 1 | 2014 | 57 | 0.100 |
Why?
| | Food Hypersensitivity | 1 | 2016 | 164 | 0.100 |
Why?
| | Teaching | 1 | 2016 | 237 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 261 | 0.100 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 363 | 0.100 |
Why?
| | Obesity | 2 | 2017 | 3116 | 0.100 |
Why?
| | Prognosis | 2 | 2016 | 4316 | 0.090 |
Why?
| | Virus Diseases | 1 | 2015 | 216 | 0.090 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3413 | 0.090 |
Why?
| | Overweight | 1 | 2017 | 614 | 0.090 |
Why?
| | Body Height | 2 | 2011 | 202 | 0.090 |
Why?
| | Age Factors | 3 | 2016 | 3342 | 0.090 |
Why?
| | Disease Management | 1 | 2016 | 653 | 0.090 |
Why?
| | Adaptive Clinical Trials as Topic | 2 | 2021 | 24 | 0.090 |
Why?
| | Schools | 2 | 2018 | 448 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2016 | 1061 | 0.090 |
Why?
| | Genomics | 1 | 2016 | 825 | 0.080 |
Why?
| | Recurrence | 3 | 2016 | 1138 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 881 | 0.080 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 396 | 0.080 |
Why?
| | Multicenter Studies as Topic | 2 | 2018 | 412 | 0.080 |
Why?
| | Dexamethasone | 2 | 2005 | 365 | 0.080 |
Why?
| | Immunoglobulin E | 3 | 2015 | 315 | 0.080 |
Why?
| | Symptom Flare Up | 2 | 2020 | 37 | 0.080 |
Why?
| | Vital Capacity | 3 | 2022 | 292 | 0.080 |
Why?
| | Research Design | 3 | 2021 | 1137 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2953 | 0.080 |
Why?
| | Young Adult | 4 | 2022 | 14218 | 0.080 |
Why?
| | Skin Tests | 2 | 2015 | 94 | 0.070 |
Why?
| | Drug Synergism | 2 | 2008 | 354 | 0.070 |
Why?
| | Growth | 2 | 2018 | 49 | 0.070 |
Why?
| | Time Factors | 3 | 2008 | 7123 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 969 | 0.070 |
Why?
| | Hypersensitivity | 2 | 2018 | 254 | 0.070 |
Why?
| | Immunotherapy | 1 | 2012 | 666 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1419 | 0.060 |
Why?
| | Respiratory Tract Diseases | 1 | 2008 | 175 | 0.060 |
Why?
| | Adenosine Monophosphate | 1 | 2007 | 85 | 0.060 |
Why?
| | Caregivers | 1 | 2016 | 1073 | 0.060 |
Why?
| | Drug Resistance | 2 | 2018 | 145 | 0.060 |
Why?
| | School Health Services | 1 | 2009 | 221 | 0.060 |
Why?
| | Regression Analysis | 1 | 2008 | 1001 | 0.060 |
Why?
| | Inflammation | 4 | 2005 | 2878 | 0.060 |
Why?
| | Drug Combinations | 2 | 2019 | 396 | 0.060 |
Why?
| | Treatment Failure | 2 | 2020 | 360 | 0.060 |
Why?
| | Cohort Studies | 3 | 2011 | 6013 | 0.060 |
Why?
| | Weight Gain | 1 | 2009 | 561 | 0.060 |
Why?
| | Incidence | 2 | 2016 | 2923 | 0.050 |
Why?
| | Multivariate Analysis | 1 | 2008 | 1547 | 0.050 |
Why?
| | Administration, Oral | 3 | 2013 | 866 | 0.050 |
Why?
| | Biopsy | 2 | 2005 | 1082 | 0.050 |
Why?
| | Bone Density | 1 | 2008 | 487 | 0.050 |
Why?
| | Lymphocyte Activation | 2 | 2005 | 1132 | 0.050 |
Why?
| | Eosinophil Granule Proteins | 1 | 2003 | 15 | 0.050 |
Why?
| | Logistic Models | 2 | 2010 | 2134 | 0.050 |
Why?
| | Age Distribution | 1 | 2004 | 403 | 0.050 |
Why?
| | Age of Onset | 3 | 2014 | 555 | 0.050 |
Why?
| | Sex Distribution | 1 | 2004 | 387 | 0.050 |
Why?
| | Global Health | 1 | 2006 | 403 | 0.050 |
Why?
| | Cross-Sectional Studies | 5 | 2015 | 5904 | 0.050 |
Why?
| | Health Status | 1 | 2008 | 832 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 428 | 0.040 |
Why?
| | Fungi | 1 | 2023 | 121 | 0.040 |
Why?
| | Clarithromycin | 1 | 2001 | 24 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 75 | 0.040 |
Why?
| | Research | 2 | 2022 | 430 | 0.040 |
Why?
| | Bronchi | 1 | 2003 | 263 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2006 | 578 | 0.040 |
Why?
| | Blood Proteins | 1 | 2003 | 239 | 0.040 |
Why?
| | Trachea | 1 | 2023 | 258 | 0.040 |
Why?
| | Cushing Syndrome | 1 | 2000 | 10 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2009 | 1101 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2005 | 1508 | 0.040 |
Why?
| | Dyspnea | 1 | 2022 | 250 | 0.040 |
Why?
| | Medication Adherence | 2 | 2019 | 540 | 0.040 |
Why?
| | Geography | 1 | 2021 | 187 | 0.040 |
Why?
| | Adrenal Glands | 1 | 2000 | 76 | 0.040 |
Why?
| | Moraxella | 1 | 2019 | 4 | 0.040 |
Why?
| | Carnobacteriaceae | 1 | 2019 | 3 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 280 | 0.040 |
Why?
| | Advisory Committees | 1 | 2021 | 229 | 0.040 |
Why?
| | Streptococcus | 1 | 2019 | 29 | 0.040 |
Why?
| | Staphylococcus | 1 | 2019 | 74 | 0.040 |
Why?
| | Exercise Test | 1 | 2022 | 630 | 0.040 |
Why?
| | Nasal Mucosa | 1 | 2019 | 112 | 0.040 |
Why?
| | Allergens | 1 | 2022 | 386 | 0.040 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2018 | 25 | 0.030 |
Why?
| | Animals | 2 | 2022 | 38030 | 0.030 |
Why?
| | Absenteeism | 1 | 2018 | 52 | 0.030 |
Why?
| | Prevalence | 1 | 2005 | 2865 | 0.030 |
Why?
| | Middle Aged | 6 | 2019 | 36215 | 0.030 |
Why?
| | Bacteria | 1 | 2023 | 765 | 0.030 |
Why?
| | United States | 3 | 2021 | 16098 | 0.030 |
Why?
| | Vitamin D | 1 | 2020 | 403 | 0.030 |
Why?
| | Netherlands | 1 | 2016 | 84 | 0.030 |
Why?
| | Sex Factors | 2 | 2016 | 2105 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2005 | 1996 | 0.030 |
Why?
| | Placebo Effect | 1 | 2016 | 24 | 0.030 |
Why?
| | Pharmacokinetics | 1 | 2016 | 33 | 0.030 |
Why?
| | Airway Resistance | 2 | 2006 | 38 | 0.030 |
Why?
| | Plethysmography | 2 | 2006 | 104 | 0.030 |
Why?
| | Exhalation | 1 | 2015 | 29 | 0.030 |
Why?
| | Anaphylaxis | 1 | 2016 | 102 | 0.030 |
Why?
| | Fever | 1 | 2016 | 319 | 0.030 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2014 | 18 | 0.030 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 1 | 2014 | 7 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 185 | 0.030 |
Why?
| | Leukotriene E4 | 1 | 2013 | 24 | 0.020 |
Why?
| | Needs Assessment | 1 | 2016 | 402 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1266 | 0.020 |
Why?
| | Morbidity | 1 | 2014 | 322 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1041 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1036 | 0.020 |
Why?
| | Hypertension | 1 | 2000 | 1273 | 0.020 |
Why?
| | Prednisolone | 1 | 2011 | 67 | 0.020 |
Why?
| | Colorado | 2 | 2014 | 4553 | 0.020 |
Why?
| | Pain | 1 | 2016 | 789 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2014 | 401 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1407 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2158 | 0.020 |
Why?
| | Body Mass Index | 1 | 2017 | 2445 | 0.020 |
Why?
| | Curriculum | 1 | 2016 | 1070 | 0.020 |
Why?
| | Poverty | 1 | 2012 | 526 | 0.020 |
Why?
| | Eosinophil Cationic Protein | 1 | 2008 | 9 | 0.020 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 58 | 0.020 |
Why?
| | Factor Analysis, Statistical | 1 | 2008 | 291 | 0.020 |
Why?
| | Body Weight | 1 | 2011 | 971 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5423 | 0.020 |
Why?
| | Insurance, Health | 1 | 2009 | 310 | 0.020 |
Why?
| | Birth Weight | 1 | 2009 | 514 | 0.010 |
Why?
| | Lung Volume Measurements | 1 | 2006 | 46 | 0.010 |
Why?
| | Oscillometry | 1 | 2006 | 35 | 0.010 |
Why?
| | Retrospective Studies | 3 | 2014 | 17291 | 0.010 |
Why?
| | Biomedical Research | 1 | 2012 | 717 | 0.010 |
Why?
| | Inhibitory Concentration 50 | 1 | 2005 | 90 | 0.010 |
Why?
| | Respiratory Hypersensitivity | 1 | 2005 | 65 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 2121 | 0.010 |
Why?
| | Basement Membrane | 1 | 2003 | 32 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2000 | 3922 | 0.010 |
Why?
| | Reference Values | 1 | 2005 | 798 | 0.010 |
Why?
| | Interleukins | 1 | 2005 | 248 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1048 | 0.010 |
Why?
| | Fractures, Bone | 1 | 2008 | 428 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2003 | 153 | 0.010 |
Why?
| | Immune Tolerance | 1 | 2005 | 385 | 0.010 |
Why?
| | Bronchoscopy | 1 | 2003 | 227 | 0.010 |
Why?
| | Steroids | 1 | 2002 | 160 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1997 | 0.010 |
Why?
| | Gene Expression | 1 | 2005 | 1476 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2005 | 2803 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 6066 | 0.010 |
Why?
| | Pilot Projects | 1 | 2001 | 1891 | 0.010 |
Why?
| | Aged | 2 | 2005 | 26153 | 0.010 |
Why?
|
|
Covar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|